## Diversified Financials | Company Research

Bringing China to the World


29 April 2015

# 买入

# 维持

#### Market Data: April,28 Closing Price (HK\$) 25.60 Price Target (HK\$) 31.60 HSCEI 14,715 HSCCI 5,591 52-week High/Low (HK\$) 27.90/10.64 Market Cap (USD Mn) 32,159 Market Cap (HK\$ Mn) 249,203 Shares Outstanding (Mn) 9.585 Exchange Rate (RMB-HK\$) 1.27

### Price Performance Chart:



Source: Bloomberg

### Analyst

### Yi Zhang A0230514090002 **BED999**

zhangyi@swsresearch.com (8621)23297818×7275

## **Related Reports**

"HAITONG SECURITIES (6837:HK) -Safe play" Jan 19,2015 "HAITONG SECURITIES (6837:HK) -New share issuance" Dec 23,2014 "HAITONG SECURITIES (6837:HK) -Positive spread" Nov 24,2014

The company does not hold any equities or derivatives of the listed company mentioned in this report ("target"), but then we shall provide financial advisory services subject to the relevant laws and regulations. Any affiliates of the company may hold equities of the target, which may exceed 1 percent of issued shares subject to the relevant laws and regulations. The company may also provide investment banking services to the target. The Company fulfills its duty of disclosure within its sphere of knowledge. The clients may contact compliance@swsresearch.com for relevant disclosure materials or log into www.swsresearch.com under disclosure column for further information. The clients shall have a comprehensive understanding of the disclosure and disclaimer upon the last page.

# 成长继续

# 海通证券(6837:HK)

Financial summary and valuation								
	2013	2014	2015E	2016E	2017E			
Revenue (Rmbm)	12,803	23,446	41,311	47,433	56,761			
YoY (%)	19.97	83.13	76.20	14.82	19.67			
Net income (Rmbm)	4,281	7,711	16,642	19,127	23,938			
YoY (%)	31.63	91.09	115.84	14.93	25.16			
EPS (Rmb)	0.42	0.80	1.45	1.66	2.08			
Diluted EPS (Rmb)	0.42	0.80	1.45	1.66	2.08			
ROE (%)	6.68	10.93	13.02	12.05	12.18			
Debt/asset (%)	62.10	79.51	70.95	71.41	72.08			
Dividend Yield (%)	0.59	1.48	2.14	2.46	3.07			
PE (x)	48.37	25.3	14.0	12.2	9.8			
PB (x)	3.17	2.8	2.5	2.0	1.6			

Note: Diluted EPS is calculated as if all outstanding convertible securities, such as convertible preferred shares, convertible debentures, stock options and warrants, were exercised

**2015 年一季报强劲增长。**海通证券宣布 2015 一季度归属母公司净利润同比增长 238.4% 至人民币 41 亿元, 每股收益同比增长 230.8%至人民币 0.43 元, 加权平均净资产收益率 增长 3.86 个百分点至 5.81%。

经纪业务持续增长。2015年一季度,经纪业务净收入同比增长156.1%至人民币22亿元, 主要由于日均成交额同比增长 244. 5%至人民币 7193 亿元。海通证券的经纪业务市占率在 佣金率持续下降的环境下保持增长,从 2014 年一季度的 4.43%增长到 2015 年一季度的 4.88%。

**创新业务和投资收益持续发展。**融资融券余额同比增长 236. 5%至人民币 799 亿元,市场 份额在从 2014 年一季度的 6%下降到 2015 年一季度的 5.34%。利息收入强劲增长至人民币 13亿元,同比增长80.6%,较高的利息收入主要由融资融券业务驱动。投资收益同比增长 179%至 26 亿元。投资收益同比增 179%至 26 亿, 主要是由于持有投资收益和出售金融资 产的公允价值变动损益的增加。同时,总收入在很大程度上抵消了融资业务坏账准备和应 收融资租赁款减值损失的增加。

**资产负债表继续扩张。**资产端,总资产同比增长 16%至人民币 4091 亿元,增长主要来自 保证金贷款增加驱动(同比增长 38.7%),以及各结算应收账款的增加(同比增长 387%)。 负债端,增长主要来自经纪业务客户应付款项(同比增长82.3%),应付利息(同比增长 78.4%) 和短期借款(同比增长 110.3%)。

维持买入。我们将 2015 的日均成交额从 5000 亿上调至 8000 亿, 因此我们提高我们的 EPS 预测在 15E 从人民币 1. 22 至人民币 1. 45(同比增长 80%),预测 2016E/2017E 的 EPS 分 别为人民别 1.66/2.08,分别同比增长 15%和 25%。我们将目标价从 22.7港元上调至 31.6 港元, 代表 3.08x 15E PB。目标价还有 23.6%的上升空间, 我们维持买入建议。



**Robust results.** Haitong Securities reported 2014 net profit of Rmb4.1bn (+238.9% YoY), resulting in EPS of Rmb0.43 (+230.8% YoY), ROA increased from 1.95% in 2014 to 5.81%.

**Brokerage business continued to thrive.** In 1Q2015, net income from brokerage business increased 156.1% YoY to Rmb2.2bn, mainly driven by 244.5% YoY growth in A-share daily turnover at an average of Rmb719.3bn in 1Q15. Brokerage market share expanded from 4.43% at March-2014 to 4.88% at March-2015, even with fierce commission rate competition in the industry.

New businesses and investment gains continued to grow. Margin financing balance, up 236.5% YoY to Rmb79.9bn, market share fell from 6.00% at March-2014 to 5.34% at March-2015. Interest income increased robustly to Rmb1.3bn, up 80.6% YoY, driven by the continuing growth in margin financing business. Investment gains increased 179.0% YoY to Rmb2.6bn, mainly due to the increase in investment gains from holding and selling of financial assets at fair value through profit or loss. At the same time, total earnings was largely offset by an increase in provision for bad debts for financing business and increase in impairment loss of finance lease receivables.

**Balance sheet expansion.** In terms of the balance sheet, total assets were up by 16.0% YoY to Rmb409.1bn, primarily driven by increase in margin loan (+38.7% YoY), and an increase in various settlement receivables (+387.0% YoY). On the liabilities side, the key drivers were accounts payable to brokerage clients (+82.3% YoY), interest payable (+78.4% YoY) and the short-term borrowings (+110.3% YoY).

**Maintain BUY.** We raise our turnover forecasts from Rmb500bn to Rmb800bn in 15E.We thus upgrade our EPS forecasts from Rmb1.22 to Rmb1.45 in 15E (+80% YoY), and forecast 16E/17 EPS of Rmb1.66 in 16E (+15% YoY) and Rmb2.08 (+25% YoY). We lift our target price from HK\$22.7 to HK\$31.6, representing 3.08x 15E PB. With 23.6% upside, we maintain our BUY recommendation.

# **Appendix**

**Figure 1: Forecast Income Statement** 

Rmbm	2013	2014	2015E	2016E	2017E
Revenue					
Commission and fee income	6,751	9,295	17,923	16,197	17,039
Interest income	3,671	7,700	15,721	22,118	28,870
Net investment gains	2,150	5,709	6,850	8,220	9,865
Total revenue	12,572	22,704	40,494	46,535	55,774
Other income and gains	231	742	816	898	988
Total revenue and other income	12,803	23,446	41,311	47,433	56,761
Depreciation and amortization	307	284	299	313	329
Staff costs	2,621	4,131	5,371	6,982	9,076
Commissions to account executives	334	427	1,038	872	756
Brokerage, commissions and other transaction exp	514	868	2,363	2,109	2,123
Interest expenses	1,484	4,340	5,642	6,771	7,448
Other operating expenses	2,203	3,362	3,699	4,069	4,069
Total expenses	7,465	13,414	18,411	21,115	23,801
Share of result of an associate	117	167	192	221	254
Profit before income tax	5,455	10,199	23,092	26,539	33,215
Income tax expense	1,174	2,301	5,542	6,369	7,972
Profit for the year	4,281	7,898	17,550	20,170	25,243
Attributable to:					
Owners of the Company	4,035	7,711	16,642	19,127	23,938
Non-controlling interests	246	408	908	1,043	1,305

Source: Company data, SWS Research

**Figure 2: Forecast Balance Sheet:** 

Rmbm	2013	2014	2015E	2016E	2017E
Non-current assets					
Property and equipment	1171.60	1210.15	1270.65	1334.18	1400.89
Goodwill	623.07	2600.62	2600.62	2600.62	2600.62
Other intangible assets	256.13	254.79	254.79	254.79	254.79
Investments accounted for using equity method	2231.27	5686.14	6254.76	6880.23	7568.25
Available-for-sale investments	4720.91	8714.79	10457.74	12549.29	15059.15
Deferred tax assets	430.94	566.82	651.84	749.62	862.06
Total non-current assets	13,077.44	48,996.08	56,447.16	65,314.42	75,873.94
Current assets		1,000			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Loans and advances to customers	26531.10	64883.36	65252.01	82601.22	105648.23
Accounts receivable	1647.26	4384.35	5217.38	6208.68	7388.33
Other receivables and prepayments	1889.35	2453.97	2576.67	2705.50	2840.78
Available-for-sale investments	4951.87	3990.61	4788.73	5746.48	6895.77
Loan and receivable investments	2086.06	3347.03	3347.03	3347.03	3347.03
Held-to-maturity investments	281.61	3.01	3.61	4.33	5.19
Financial assets held under resale agreements	9036.99	52873.46	63448.15	76137.78	91365.33
Financial assets at fair value through profit or loss	47590.05	56273.06	73154.97	87785.97	105343.16
Deposits with exchanges	3693.84	5495.66	6320.01	7268.02	8358.22
Clearing settlement funds	5751.05	14818.88	17782.65	21339.18	25607.02
Bank balances and cash	52586.99	85703.61	151979.80	210276.74	291910.77
Total current assets	156046.16	303626.07	405149.90	516955.59	664951.44
Total assets	169,123.60	352,622.15	461,597.06	582,270.02	740,825.37
Current liabilities		·	·		,
Borrowings	5796.40	19807.57	22778.71	25056.58	27562.24
Short-term financing bills payables	3000.00	22926.59	5000.00	5000.00	5000.00
Placements from other financial institutions	1120.00	14270.00	16410.50	18872.08	21702.89
Accounts payable to brokerage clients	40429.57	80766.84	121150.26	169610.37	237454.52
Other payables and accruals	3295.50	7697.58	10006.85	13008.90	16911.57
Tax liabilities	2.74	2.49	2.49	2.49	2.49
Financial liabilities at fair value through profit or loss					
i manciai nabilities at fair value tillough profit of 1033	395.28	816.78	939.29	1080.18	1242.21
Financial assets sold under repurchase agreements				1080.18 25398.24	1242.21 33017.71
<b>3</b> 1	395.28	816.78	939.29		
Financial assets sold under repurchase agreements	395.28 6506.51	816.78 15028.55	939.29 19537.11	25398.24	33017.71
Financial assets sold under repurchase agreements  Total current liabilities	395.28 6506.51 26111.91	816.78 15028.55 59807.86	939.29 19537.11 71769.44	25398.24 86123.32	33017.71 103347.99
Financial assets sold under repurchase agreements  Total current liabilities  Net current assets	395.28 6506.51 26111.91 <b>86657.90</b>	816.78 15028.55 59807.86 <b>221124.26</b>	939.29 19537.11 71769.44 <b>267594.65</b>	25398.24 86123.32 <b>344152.17</b>	33017.71 103347.99 <b>446241.63</b>
Financial assets sold under repurchase agreements  Total current liabilities  Net current assets  Net assets	395.28 6506.51 26111.91 <b>86657.90</b>	816.78 15028.55 59807.86 <b>221124.26</b>	939.29 19537.11 71769.44 <b>267594.65</b>	25398.24 86123.32 <b>344152.17</b>	33017.71 103347.99 <b>446241.63</b>
Financial assets sold under repurchase agreements  Total current liabilities  Net current assets  Net assets  Equity	395.28 6506.51 26111.91 <b>86657.90</b> 64105.16	816.78 15028.55 59807.86 <b>221124.26</b> 72264.20	939.29 19537.11 71769.44 <b>267594.65</b> 132269.77	25398.24 86123.32 <b>344152.17</b> 164038.68	33017.71 103347.99 <b>446241.63</b> 205688.75
Financial assets sold under repurchase agreements  Total current liabilities  Net current assets  Net assets  Equity  Share capital	395.28 6506.51 26111.91 <b>86657.90</b> 64105.16	816.78 15028.55 59807.86 <b>221124.26</b> 72264.20	939.29 19537.11 71769.44 <b>267594.65</b> 132269.77	25398.24 86123.32 <b>344152.17</b> 164038.68 11501.70	33017.71 103347.99 <b>446241.63</b> 205688.75
Financial assets sold under repurchase agreements  Total current liabilities  Net current assets  Net assets  Equity  Share capital  Reserves	395.28 6506.51 26111.91 <b>86657.90</b> 64105.16 9,584.72 32383.07	816.78 15028.55 59807.86 <b>221124.26</b> 72264.20 9,584.72 32383.60	939.29 19537.11 71769.44 <b>267594.65</b> 132269.77 11501.70 32383.60	25398.24 86123.32 <b>344152.17</b> 164038.68 11501.70 32383.60	33017.71 103347.99 446241.63 205688.75 11501.70 32383.60
Financial assets sold under repurchase agreements  Total current liabilities  Net current assets  Net assets  Equity  Share capital  Reserves  Retained profits	395.28 6506.51 26111.91 <b>86657.90</b> 64105.16 9,584.72 32383.07 11780.55	816.78 15028.55 59807.86 <b>221124.26</b> 72264.20 9,584.72 32383.60 16557.45	939.29 19537.11 71769.44 <b>267594.65</b> 132269.77 11501.70 32383.60 33514.98	25398.24 86123.32 <b>344152.17</b> 164038.68 11501.70 32383.60 56810.45	33017.71 103347.99 446241.63 205688.75 11501.70 32383.60 88323.11
Financial assets sold under repurchase agreements  Total current liabilities  Net current assets  Net assets  Equity  Share capital  Reserves  Retained profits  Equity attributable to owners of the company	395.28 6506.51 26111.91 <b>86657.90</b> 64105.16 9,584.72 32383.07 11780.55 <b>61506.99</b>	816.78 15028.55 59807.86 <b>221124.26</b> 72264.20 9,584.72 32383.60 16557.45 <b>68364.43</b>	939.29 19537.11 71769.44 <b>267594.65</b> 132269.77 11501.70 32383.60 33514.98 <b>87320.43</b>	25398.24 86123.32 <b>344152.17</b> 164038.68 11501.70 32383.60 56810.45 <b>110713.68</b>	33017.71 103347.99 446241.63 205688.75 11501.70 32383.60 88323.11 142343.68

Source : Company data, SWS Research

### **Information Disclosure:**

The views expressed in this report accurately reflect the personal views of the analyst. The analyst declares that neither he/she nor his/her associate serves as an officer of nor has any financial interests in relation to the listed corporation reviewed by the analyst. None of the listed corporations reviewed or any third party has provided or agreed to provide any compensation or other benefits in connection with this report to any of the analyst, the Company or the group company(ies). A group company(ies) of the Company confirm that they, whether individually or as a group (i) are not involved in any market making activities for any of the listed corporation reviewed; or (ii) do not have any individual employed by or associated with any group company(ies) of the Company serving as an officer of any of the listed corporation reviewed; or (iii) do not have any financial interest in relation to the listed corporation reviewed or (iv) do not, presently or within the last 12 months, have any investment banking relationship with the listed corporation reviewed.

#### Undertakings of the Analyst

I (We) am (are) conferred the Professional Quality of Securities Investment Consulting Industry by the Securities Association of China and have registered as the Securities Analyst. I hereby issue this report independently and objectively with due diligence, professional and prudent research methods and only legitimate information is used in this report. I am also responsible for the content and opinions of this report. I have never been, am not, and will not be compensated directly or indirectly in any form for the specific recommendations or opinions herein.

Disclosure with respect to the Company

The company is a subsidiary of Shenwan Hongyuan Securities. The company is a qualified securities investment consulting institute approved by China Securities Regulatory Commission with the code number ZX0065.

Releasing securities research reports is the basic form of the securities investment consulting services. The company may analyze the values or market trends of securities and related products or other relevant affecting factors, provide investment analysis advice on securities valuation/ investment rating, etc. by issuing securities research reports solely to its clients.

The Company fulfills its duty of disclosure within its sphere of knowledge. The clients may contact <a href="mailto:compliance@swsresearch.com">compliance@swsresearch.com</a> for the relevant disclosure materials or log into <a href="mailto:www.swsresearch.com">www.swsresearch.com</a> for the analysts' qualifications ', the arrangement of the quiet period and the affiliates' shareholdings.

Introduction of Share Investment Rating

Security Investment Rating:

When measuring the difference between the markup of the security and that of the market's benchmark within six months after the release of this report, we define the terms as follows:

Trading BUY: Share price performance is expected to generate more than 20% upside over a 6-month period.

BUY: Share price performance is expected to generate more than 20% upside over a 12-month period.

Outperform: Share price performance is expected to generate between 10-20% upside over a 12-month period.

Hold: Share price performance is expected to generate between 10% downside to 10% upside over a 12-month period.

Underperform: Share price performance is expected to generate between 10-20% downside over a 12-month period.

SELL: Share price performance is expected to generate more than 20% downside over a 12-month period.

**Industry Investment Rating:** 

When measuring the difference between the markup of the industry index and that of the market's benchmark within six months after the release of the report, we define the terms as follows:

Overweight: Industry performs better than that of the whole market;

Equal weight: Industry performs about the same as that of the whole market;

Underweight: Industry performs worse than that of the whole market.

We would like to remind you that different security research institutions adopt different rating terminologies and rating standards. We adopt the relative rating method to recommend the relative weightings of investment. The clients' decisions to buy or sell securities shall be based on their actual situation, such as their portfolio structures and other necessary factors. The clients shall read through the whole report so as to obtain the complete opinions and information and shall not rely solely on the investment ratings to reach a conclusion. The Company employs its own industry classification system. The industry classification is available at our sales personnel if you are interested.

HSCEI is the benchmark employed in this report.

### Disclaimer:

This report is to be used solely by the clients of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities, hereinafter referred to as the "Company"). The Company will not deem any other person as its client notwithstanding his receipt of this report.

This report is based on public information, however, the authenticity, accuracy or completeness of such information is not warranted by the Company. The materials, tools, opinions and speculations contained herein are for the clients' reference only, and are not to be regarded or deemed as an invitation for the sale or purchase of any security or other investment instruments.

The clients understand that the text message reminder and telephone recommendation are no more than a brief communication of the research opinions, which are subject to the complete report released on the Company's website (<a href="http://www.swsresearch.com">http://www.swsresearch.com</a>). The clients may ask for follow-up explanations if they so wish.

The materials, opinions and estimates contained herein only reflect the judgment of the Company on the day this report is released. The prices, values and investment returns of the securities or investment instruments referred to herein may fluctuate. At different periods, the Company may release reports which are inconsistent with the materials, opinions and estimates contained herein.

Save and except as otherwise stipulated in this report, the contactor upon the first page of the report only acts as the liaison who shall not provide any consulting services.

The clients shall consider the Company's possible conflict of interests which may affect the objectivity of this report, and shall not base their investment decisions solely on this report. The clients should make investment decisions independently and solely at your own risk. Please be reminded that in any event, the company will not share gains or losses of any securities investment with the clients. Whether written or oral, any commitment to share gains or losses of securities investment is invalid. The investment and services referred to herein may not be suitable for certain clients and shall not constitute personal advice for individual clients. The Company does not ensure that this report fully takes into consideration of the particular investment objectives, financial situations or needs of individual clients. The Company strongly suggests the clients to consider themselves whether the opinions or suggestions herein are suitable for the clients' particular situations; and to consult an independent investment consultant if necessary.

Under no circumstances shall the information contained herein or the opinions expressed herein forms an investment recommendation to anyone. Under no circumstances shall the Company be held responsible for any loss caused by the use of any contents herein by anyone. Please be particularly cautious to the risks and exposures of the market via investment.



Independent investment consultant should be consulted before any investment decision is rendered based on this report or at any request of explanation for this report where the receiver of this report is not a client of the Company.

The Company possesses all copyrights of this report which shall be treated as non-public information. The Company reserves all rights related to this report. Unless otherwise indicated in writing, all the copyrights of all the materials herein belong to the Company. In the absence of any prior authorization by the Company in writing, no part of this report shall be copied, photocopied, replicated or redistributed to any other person in any form by any means, or be used in any other ways which will infringe upon the copyrights of the Company. All the trademarks, service marks and marks used herein are trademarks, service marks or marks of the Company, and no one shall have the right to use them at any circumstances without the prior consent of the Company.

This report may be translated into different languages. The Company does not warrant that the translations are free from errors or discrepancies. This report is for distribution in Hong Kong only to persons who fall within the definition of professional investors whether under the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) (the "SFO") or the Securities and Futures (Professional Investor) Rules (Chapter 571D of the laws of the Hong Kong under the SFO).

This report is for distribution in the United Kingdom only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) order 2001 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc") of the Order (All such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons. Other Persons who are not Relevant Persons must not act or rely upon this document or any of its contents.

### Disclaimer

This report was prepared, approved, published and distributed by the SWS Research Co., Ltd (subsidiary of Shenwan Hongyuan Securities) located outside of the United States (a "non-US Group Company"). This report is distributed in the U.S. by Enclave Capital LLC, a U.S. registered broker dealer, on behalf of SWS Research Co., Ltd only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act")) pursuant to the exemption in Rule 15a-6 and any transaction effected by a U.S. customer in the securities described in this report must be effected through Enclave Capital LLC (19 West 44th Street, suite 1700, New York, NY 10036).

Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization. The information has been compiled or arrived from sources believed to be reliable and in good faith, but no representation or warranty, express or implied is made as to their accuracy, completeness or correctness. SWS Research Co., Ltd. (a subsidiary of Shenwan Hongyuan Securities) accepts no liability whatsoever for any direct or consequential loss or damage arising from (i) the use of this communication (ii) reliance of any information contained herein, (iii) any error, omission or inaccuracy in any such Information or (iv) any action resulting there from. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) provides the information for the purpose of the intended recipient's analysis and review. Accordingly you are advised to verify the factual accuracy, assumptions, calculations or completeness of the information.

### **Analyst Certification**

Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report.

### **Important US Regulatory Disclosures on Subject Companies**

This material was produced by SWS Research Co., Ltd. ( subsidiary of Shenwan Hongyuan Securities ) solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. It is distributed in the United States of America by Enclave Capital LLC and elsewhere in the world by SWS Research Co., Ltd. ( subsidiary of Shenwan Hongyuan Securities ) or an authorized affiliate of SWS Research Co., Ltd. ( subsidiary of Shenwan Hongyuan Securities ) or its affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which SWS Research Co., Ltd. ( subsidiary of Shenwan Hongyuan Securities ) or its Affiliates consider to be reliable. None of SWS Research Co., Ltd. ( subsidiary of Shenwan Hongyuan Securities ) accepts any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions.

- 1. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates have not recently been the beneficial owners of 1% or more of the securities mentioned in this report.
- 2. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates have not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
- 3. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates have not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
- 4. However, one or more person of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities ) or its affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon either on their own account or on behalf of their clients.
- 5. As of the publication of this report Enclave Capital LLC, does not make a market in the subject securities.
- 6. SWS Research Co., Ltd. ( subsidiary of Shenwan Hongyuan Securities ) or its Affiliates may, to the extent permitted by law, act upon or use the above material or the conclusions stated above or the research or analysis on which they are based before the material is published to recipients and from time to time provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report

### **Distribution in Singapore**

If distributed in Singapore, this report is meant only for Accredited Investors and Institutional Investors as defined under Section 4A of the Securities and Futures Act of Singapore. If you are not an Accredited Investor or an Institutional Investor, you shall ignore the report and its contents. The Singapore recipients of the report are to contact the Singapore office of Shenyin Wanguo Singapore Private Limited at 65-6323-5208, or 65-6323-5209 in respect of any matters arising from, or in connection with, the report.